Meridian Bioscience

The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

Within the company's diagnostics segment, revenues for molecular assays in particular declined 21 percent year over year.

The company drew $49 from the credit facility to repay an earlier outstanding loan and expects to draw another $27 million to, in part, pay for its acquisition of GenePOC.

The test is the fourth assay on the firm's Revogene system and it detects five common genetic causes of drug resistance.

The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.

The firm will acquire GenePOC for $50 million with potential for milestone payments of an addition $70 million by Meridian's fiscal 2023.